News for Nippon Shinyaku Co., Ltd. (4516.T)

PR NewswirePARAMUS, N.J., May 14, 2025 PARAMUS, N.J., May 14, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (

Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a t

Company to Host Conference Call, May 13, 2025 at 4:30 p.m. ET SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics ( CAPR), a biotechnology com

-Company remains on track for PDUFA target action date of August 31, 2025- -Advisory committee meeting to be held in advance of target action date-

**media[614527]**

**media[595441]**

**media[583704]**

Announced the U.S. FDA has accepted our Biologics License Application (BLA) seeking full approval of deramiocel for the treatment of Duchenne muscular dystrophy

--Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease-- --Data Presented at the 2025 Muscular Dystrophy Ass

**media[564244]**

Company to Host Conference Call, March 19, 2025 at 4:30 p.m. ET SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics ( CAPR), a biotechnology

PR NewswirePARAMUS, N.J., March 10, 2025 PARAMUS, N.J., March 10, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Lt

**media[560229]**

**media[556676]**

**media[536796]**

**media[524739]**

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone payme

**media[504255]**